sweetlou, another excellent, scientific, balanced and professional response. Thanks!
The 14 years of being out there with no negative side effects is a very good thing. Weight loss would generally be considered a positive side effect, unless a person was emaciated, then Sucanon might not be a good choice for that individual. But then most type 2 diabetics are overweight and not underweight.
As for the future of Roth and Sucanon, this will be determined by expansion into new (countries) markets and resulting sales. There is a huge potential as type 2 diabetes is growing and becoming a world wide epidemic. There is a huge market that is only growing. I believe that once a major distribution agreement is signed and marketed successfully through doctors, hospitals and clinics, Sucanon sales and stock price will rise in lock-step. If /when this occurs it will be "off to the races" and many will be kicking themselves for not buying in at 1/2 cent.
News 
Market Data 
Discover 
AI
